Aurinia pharmaceuticals reports third quarter and nine months 2024 financial and operational results, announces strategic restructuring to sharpen focus on continued lupkynis® growth and aur200 development

Rockville, md. & edmonton, alberta--(business wire)--aurinia pharmaceuticals inc. (nasdaq: auph) (aurinia or the company) today issued its financial results for the third quarter and nine months ended september 30, 2024. with continued strong commercial execution, the company achieved significant year-over-year growth in total net revenue and net product revenue and $17.0 million in cash flow from operations in the third quarter. having achieved $158.6 million in net product revenue for the nin.
AUR Ratings Summary
AUR Quant Ranking